| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.09 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.09 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.075 | 0.09 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.09 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |